Back to News
May 18, 2026 4:00 PM

Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal

Boston Scientific Corporation (NYSE:BSX) said it invested $1.5 billion in privately held MiRus, securing an approximately 34% equity stake and an exclusive option to acquire the company's investigational transcatheter aortic valve replacement (TAVR) business.

• Boston Scientific shares are powering higher. Why is BSX stock surging?

The investment gives Boston Scientific access to the SIEGEL Balloon Expandable TAVR system, a nickel-free valve platform designed to treat severe aortic stenosis. The device remains investigational and has not been approved for commercial distribution in any country.

The company said the transaction aligns with its strategy to strengthen its cardiovascular portfolio.

Under the agreement, Boston Scientific may acquire the MiRus TAVR business through additional cash payments totaling $3 billion if specified clinical and regulatory milestones are achieved.